Bimatoprost/Brimonidine

贝美前列素/溴莫尼定

Report date: 2023/09/15 15:14:14

Base Information

Drug NameBimatoprost/Brimonidine
Drug Alias Name贝美前列素•溴莫尼定Bimatoprost+BrimonidineBimatoprost-Brimonidine贝美前列素和溴莫尼定Bimatoprost•Brimonidine +[11] 
ClassificationSmall molecules
Mechanisms of ActionAdrenergic receptors alpha-2 agonistsProstanoid receptor agonists
TargetsProstanoid receptorAdrenergic receptors alpha-2
Therapy Area/IndicationsGlaucomaOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes BimatoprostBrimonidine Tartrate
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAllergan Plc
Active IndicationsN/A
Inactive IndicationsGlaucomaOcular Hypertension

Other Information

ATC CodeN/A
Related LinksN/A